Navigation Links
DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
Date:8/4/2011

top-line results from a Phase II clinical trial conducted by King for the treatment of chronic low back pain.  The primary efficacy endpoint for the trial was not met.  We and Pfizer are continuing to analyze these data and will work together to determine next steps for ELADUR.ELADUR is our proprietary transdermal patch intended to deliver bupivacaine for a period of up to three days from a single application.  ELADUR demonstrated a positive efficacy trend in a Phase 2a study for post-herpetic neuralgia (PHN); a poster describing this study was presented at the 27th Annual Scientific Meeting of the American Pain Society on May 8, 2008 and is accessible on DURECT's website at www.durect.com/wt/durect/page_name/Publications.


  • TRANSDUR-Sufentanil.  In recent months, we have had discussions with the FDA and regulatory agencies in several major European countries to better understand development requirements for U.S. and European approval in furtherance of our development plans for TRANSDUR-Sufentanil.  We continue discussions with potential partners regarding licensing development and commercialization rights to this program to which we hold worldwide rights.TRANSDUR-Sufentanil is our proprietary transdermal patch intended to deliver sufentanil to chronic pain sufferers for a period of up to seven days from a single application.


  • ORADUR-ADHD Program.  In the second quarter of 2011, we and Orient Pharma completed a Phase I pharmacokinetic study with multiple formulations.  We are continuing to optimize the formulation and are planning next steps in our ORADUR-ADHD program.


  • Relday™ (Risperidone Program).  In July 2011, we signed a development and license agreement with Zogenix to develop Relday, a product candidate targeting the antipsy
    '/>"/>


  • SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
    2. DURECT to Present at the Jefferies Healthcare Conference
    3. DURECT Announces Resignation of Chief Medical Officer
    4. DURECT to Present at the UBS Global Specialty Pharmaceuticals Conference
    5. DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
    6. DURECT to Present at Cowen and Company Health Care Conference
    7. DURECT Corporation Invites You to Join its Fourth Quarter 2010 Earnings Conference Call
    8. DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
    9. DURECT Announces Launch of First FDA Approved SABER™-Injectable Peptide Product
    10. DURECT to Present at the BIO CEO & Investor Conference
    11. DURECT to Present at the Credit Suisse 2010 Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... , Aug. 27, 2014  UBM Medica US ... leading online community for medical imaging professionals, presents special ... for Medical Imaging Management,s 2014 Annual Meeting . ... coverage: , 11 Principles of Successful ... lead to greater profitability. , Why Don,t ...
    (Date:8/27/2014)... 2014 /PRNewswire-iReach/ -- "Fatty Liver Disease Global Clinical Trials ... Disease clinical trial scenario. This report provides elemental information ... Fatty Liver Disease . It includes an overview of ... the site of trial conduction across the globe. The ... by their phase, trial status, prominence of the sponsors ...
    (Date:8/27/2014)... CITY, Calif. , Aug. 27, 2014 /PRNewswire-iReach/ ... emergency response system design, blended emergency medical training ... CPR/AED (automated external defibrillator) training from the ... the Army Reserve 81 st Regional ... Security and Investigations contract includes nationwide CPR/AED/First Aid ...
    Breaking Medicine Technology:Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 2Emergency University Equips Homeland Security, Army Reserve with SCA Response Program to Save Lives of Sudden Cardiac Arrest Victims 3
    ... ... ... - SORT OUT III Data Presented at American College of Cardiology Meeting,in Atlanta and Published in the Lancet , ... , , ...
    ... Md. , March 17 Micromet, Inc. (Nasdaq: MITI ) announced today the closing of its previously ... shares of common stock. As a result, Micromet sold a total of 11.5 million shares of its common stock at ... ... , , ...
    Cached Medicine Technology:Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 2Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 3Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 4Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 5Positive Long Term Data Presented at ACC 2010 Demonstrate Sustained Safety and Efficacy Advantages of the Cypher(R) Sirolimus Drug-Eluting Stent Over the Endeavor(R) Zotarolimus-Eluting Stent 6Micromet Closes $80.5 Million Public Offering of Common Stock 2Micromet Closes $80.5 Million Public Offering of Common Stock 3Micromet Closes $80.5 Million Public Offering of Common Stock 4
    (Date:8/27/2014)... 27, 2014 With most forms ... sense to use hearing protection when exposed to ... are many different forms of hearing protection ... provide hearing protection training and devices for workers ... industries. The National Institute of Occupational Safety and ...
    (Date:8/27/2014)... time you experienced worrisome medical symptoms, did you ... professional? If so, you,re not alone. Consumers are ... support groups to gather anecdotal information and advice, ... trustworthy sources. New research to be presented at ... the characteristics of consumers who use the Internet ...
    (Date:8/27/2014)... 27, 2014 (HealthDay News) -- A new genetic discovery ... fight the bowel disorder, researchers report. The ... affect how their genes work, and said these changes ... raising the possibility of a simple diagnostic test for ... disease develops and suggest possible gene targets for new ...
    (Date:8/27/2014)... An experimental drug designed to help regulate the blood,s iron ... of inflammation, according to results from the first human ... Blood , the Journal of the American ... occurs when red blood cells are in short supply or ... body does not get enough oxygen, since there are fewer ...
    (Date:8/27/2014)... 8/27/14)Dartmouth cancer researchers developed and tested an advanced ... interactions that contribute to disease as published yesterday ... The approach fills a gap in current analyses. ... interactions among genetic and environmental factors. When many ... versus those that reflect chance combinations among affected ...
    Breaking Medicine News(10 mins):Health News:Hearing Health Solutions Now Offering a Full Line of Occupation Hearing Protection Services and Expanded Line of Ear Protection Products 2Health News:Hearing Health Solutions Now Offering a Full Line of Occupation Hearing Protection Services and Expanded Line of Ear Protection Products 3Health News:Educated consumers more likely to use potentially unreliable online healthcare information 2Health News:Scientists Spot Genetic Clues to Crohn's Disease 2Health News:Drug represents first potential treatment for common anemia 2Health News:Dartmouth isolates environmental influences in genome-wide association studies 2
    ... 7-day old baby was charred to death due to a short ... their joy and hopes. The incubator in which the baby was ... incident had happened due to negligence of the hospital staff while ... were saved due to prompt action of the medical staff who ...
    ... The doctor, who had dismissed increased risk of heart attack ... that his views are 'out of the mainstream' as it ... company, Merck and Co. ,Thomas Cona and John ... the drug had resulted in heart attacks. More than 10, ...
    ... of the biggest problems worldwide. There is an urgent ... these new antibiotic resistant infections. // Researchers at ... say they have used natural bacteria living in soil ... discovery would allow scientists race ahead in developing antibiotics ...
    ... behind the alleged leak of question papers of the MD/MS ... India Institute of Medical Sciences (AIIMS), // has been ... Madurai Medical College. ,Satish Kumar (26),an MD (Paediatric) ... and two other doctors have been taken into custody ...
    ... (PTSD) is a disabiling anxiety disorder, which was first ... War I, as soldier's heart and shell shock respectively. ... are affected by cancer and their families as well ... affects about 10 percent of those exposed to extreme ...
    ... shared between India and China. The world's fastest growing ... to tackle the // problem of this latest threat. , ... Du Qinglin met and discussed management of avian influenza ... was agreed that exchange of information and technical cooperation between ...
    Cached Medicine News:Health News:The Face Of Indian Health Care: A World Health Day Evaluation 2Health News:The Face Of Indian Health Care: A World Health Day Evaluation 3Health News:The Face Of Indian Health Care: A World Health Day Evaluation 4Health News:Doctor Grilled In Court For False Report About Vioxx Health Risk 2Health News:New Therapy For Treating Post-Traumatic Stress Syndrome 2
    ... CVA for CELL-DYN are assayed linearity control ... and to verify patient reportable range of ... also measure the linear performance of the ... have customized ranges appropriate for each instrument ...
    The technology in the LATITUDE system allows your doctor to get the same data from your device whether you are at home or in your doctor's office. This information transfer happens automatically....
    ... Proprietary EX.P.R.T. Release ... jumping,, No stent shortening,, Unique anatomically ... in the carotid bifurcation,, 0.014 Rapid ... crossing profile and flexible atraumatic tip,, ...
    ... Para 5X is a whole blood ... Pentra 60C+, 80 and 120, and the ... product offers a unique white cell differential, ... the algorithms on the systems. The product ...
    Medicine Products: